



CVMP/SAGAM recommendations on antimicrobials

Karolina Törneke

Member of the CVMP SAGAM Chair



Committee of Medicinal Products for Veterinary Use (**CVMP**)

•CVMP prepares the EMEA's opinions on all questions concerning veterinary medicinal products

•Scientific Advisory Group on Antimicrobials (SAGAM) provides scientific input



 \star

Arkiv Redigera Visa Favoriter	Verktya Hiëlo			_
0 0	ency - Veterinary Medicines			+ (6
European Medicines Agency	ency - vecennary medicines			1.04
European Medicines Agency			Home Sitemap L	
emer			Advanced Search Search Tip	
About Us What's New Hum	an Medicines Veterinary Medicines	Inspections General Reporting		
Back to main menu	Veterinary Medicin	es - Antimicrobial Resistance		
	Scientific quidence decumente er	this topic can be found in the relevant section under Scientific guidance		
		r this topic can be found in the relevant section under <u>Scientific guitance</u>		
	General Guidance			
	EMEA/CVMP/SAGAM/68290/2009	Reflection paper on MRSA in food producing and companion animals in the European Uni- Epidemiology and control options for human and animal health	on:	
	EMEA/CVMP/SAGAM/81730/2006	 Revised reflection paper: Use of 3rd and 4th generation Cephalosporins in food-producin in the European Union: Development of resistance and impact on human and animal hea 		
		See also: EMEA/CVMP/SAGAM/464096/08 Overview of comments received		
	EMEA/CVMP/SAGAM/428938/07	Reflection Paper on antimicrobial resistance surveillance as post-marketing authorisation	1	
		commitment (CVMP adopted October 2008) <i>See also: <u>EMEA/CVMP/SAGAM/341254/2008</u> Overview of comments received</i>		
	See: <u>Veterinary QRD</u>	Reflection Paper on use of fluoroquinolones in food producing animals - Precautions for u SPC regarding prudent use guidance (EMEA/CVMP/416168/2006)	ise in the	
	EMEA/CVMP/SAGAM/184651/05	CVMP Public Statement on the use of (Fluoro) quinolones in food-producing animals in th	18	
		European Union: Development of resistance and impact on human and animal health See also: EMEA/CVMP/SAGAM/496824/2006 Overview of comments received		
	EMEA/CVMP/353297/05	CVMP Strategy on Antimicrobials 2006-2010 and Status Report on Activities on Antimicro	phials	
	Historic Guidance			
		5 Reflection Paper on Use of Fluoroquinolones in food producing animals in the European U	Jnion:	
		Development of Resistance and Impact on Human and Animal Health (End of CVMP cons May 2006)		
	EMEA/CVMP/1136/04	CVMP Involvement of SAGAM in the evaluation of applications for centralised MA contain antimicrobial substances	ling	
		antimerobial substances		

http://www.emea.europa.eu/htms/vet/antimicrobial/antimicrobial.htm



CVMP strategy on antimicrobials 2006-2010 and status report on activities on antimicrobials

- Ensure availability of antimicrobial products for veterinary use so that the use of these products is efficient, whilst safeguarding against the development of resistance
- Focus on prudent use instructions
- Work for enhanced communication and an open dialogue



CVMP strategy on antimicrobials 2006-2010 and status report on activities on antimicrobials

The focus of the CVMP work is in the prudent use instructions [in SPCs], which are considered an efficient way for controlling resistance development [...] while applying legal restrictions should only be considered as last option.



Public statement on the use of (fluoro)quinolones in food producing animals in the European union: Development of resistance and impact on human and animal health

 FQs should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials



Cont:

- The dosage regimens of FQs should be carefully determined to ensure optimal efficacy and reduce selection of resistance
- Group and flock medication is under discussion
- Plasmid mediated FQ resistance complicates the picture



Reflection paper on the use of 3rd and 4th generation cephalosporins in foodproducing animals in the European union: Development of resistance and impact on human and animal health

- Systemic broad spectrum cephalosporins should be reserved...
- Use of systemic cephalosporins for groups or flocks of animals should be discouraged
- Prophylactic use should be reserved for specific circumstances



Reflection paper on MRSA in food producing and companion animals and in the European Union: Epidemiology and control options for human and animal health

- Any measures to be taken should consider all antimicrobials with the aim to eliminate unnecessary use or replace use with other strategies.
- Use in animals of last resort medicines for MRSA treatment in humans should be avoided.



SUMMARY

- We believe in prudent use
- We believe in transparency and close collaboration with other stakeholders
- Implementation of warning texts and compliance with recommendations is crucial



Final remark



 \bigstar

The best way of reducing resistance is to make antimicrobials superfluous!

- Biosecurity
- Vaccination
- Education
- Et cetera